Leukemia, lymphoma, myeloma and myelodysplastic syndromes (MDS) are types of cancer that can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
Click on the links below to view statistics about each disease:
- Approximately every 3 minutes one person in the United States (US) is diagnosed with a blood cancer.
- An estimated combined total of 171,550 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2016.
- New cases of leukemia, lymphoma and myeloma are expected to account for 10.2 percent of the estimated 1,685,210 new cancer cases diagnosed in the US in 2016.
- Prevalence is the estimated number of people alive on a certain date in a population who previously had a diagnosis of the disease. An estimated 1,237,824 people in the US are either living with, or are in remission from, leukemia, lymphoma or myeloma.
- Relative survival compares the survival rate of a person diagnosed with a disease to that of a person without the disease. The most recent survival data available may not fully represent the outcomes of all current therapies and, as a result, may underestimate survival to a small degree.
- Approximately every 9 minutes, someone in the US dies from a blood cancer. This statistic represents approximately 160 people each day or more than six people every hour.
- Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the US in 2016.
- These diseases are expected to account for 9.8 percent of the deaths from cancer in 2016, based on the estimated total of 595,690 cancer deaths.
- In 2016, 60,140 people are expected to be diagnosed with leukemia.
- There are an estimated 345,422 people living with, or in remission from, leukemia in the US.
- The overall five-year relative survival rate for leukemia has more than quadrupled since 1960. From 1960 to 1963, the five-year relative survival rate among whites (only data available) with leukemia was 14 percent. From 1975 to 1977, the five-year relative survival rate for the total population with leukemia was 34.1 percent, and from 2005 to 2011, the overall relative survival rate was 61.7 percent.
- From 2005-2011, the five-year relative survival rates overall were
- CML - 63.2 percent
- CLL - 84.8 percent
- AML - 26 percent overall and 66.5 percent for children and adolescents younger than 15 years
- ALL - 70.1 percent overall, 91.2 percent for children and adolescents younger than 15 years, and 92.9 percent for children younger than 5 years.
- In 2016, 24,400 people are expected to die from leukemia (14,130 males and 10,270 females).
- In 2008-2012, leukemia was the fifth most common cause of cancer deaths in men and the sixth most common in women in the US.
- In 2016, there are expected to be 81,080 new cases of lymphoma diagnosed in the US (8,500 cases of HL, 72,580 cases of NHL).
- There are an estimated 788,939 people living with, or in remission from, lymphoma in the US.
- There are 181,967 people living with Hodgkin lymphoma
- There are 606,972 people living with non-Hodgkin lymphoma
- The five-year relative survival rate for people with HL has more than doubled, from 40 percent in whites from 1960-1963 (only data available) to 88.3 percent for all races in 2005-2011. The five-year relative survival rate is 94.1 percent for people with HL who were less than 45 years old at diagnosis.
- HL is now considered to be one of the most curable forms of cancer.
- The five-year relative survival rate for people with NHL has risen from 31 percent in whites from 1960-1963 (only data available) to 71.9 percent for all races in 2005-2011.
- In 2015, 21,270 people are expected to die from lymphoma (1,120 from HL, 20,150 from NHL).
- An estimated 30,330 new cases of myeloma (17,900 males and 12,430 females) are expected to be diagnosed in the US in 2016.
- An estimated 103,463 people in the US are living with, or in remission from, myeloma.
- Five-year relative survival has increased from 12 percent in 1960-1963 among whites (only data available) to 48.5 percent from 2005-2011 among all races and ethnicities.
- The three-year survival rate as of January 1, 2012, is 64 percent (for all races and ethnicities).
- Approximately 12,650 deaths from myeloma are anticipated in 2016.
- For the five-year period from 2008 to 2012 there were approximately 75,741 new cases of MDS throughout the US, averaging an estimated 15,148 cases per year.
- There were approximately 42,730 cases in males (averaging 8,546 per year) and 33,011 cases in females (averaging 6,602 per year).
- The SEER program only recently began maintaining statistics for MDS. Prevalence and mortality statistics were not reported by SEER for MDS in 2016 at the time of this publication.
- Mortality rates were not reported by SEER for MDS in 2016 at the time of this publication.
- Facts 2015-2016. The incidence, prevalence and mortality data in Facts 2015-2016 reflect the statistics from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program, Cancer Statistics Review (CSR) 1975-2012.
- Cancer Facts & Figures 2016. Atlanta, GA: American Cancer Society; 2016.